260 586

Cited 30 times in

Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment

DC Field Value Language
dc.contributor.author이병완-
dc.contributor.author차봉수-
dc.date.accessioned2019-07-11T03:33:44Z-
dc.date.available2019-07-11T03:33:44Z-
dc.date.issued2019-
dc.identifier.issn2233-6079-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/170036-
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Diabetes Association-
dc.relation.isPartOfDIABETES & METABOLISM JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleNonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorKyung-Soo Kim-
dc.contributor.googleauthorByung-Wan Lee-
dc.contributor.googleauthorYong Jin Kim-
dc.contributor.googleauthorDae Ho Lee-
dc.contributor.googleauthorBong-Soo Cha-
dc.contributor.googleauthorCheol-Young Park-
dc.identifier.doi10.4093/dmj.2019.0034-
dc.contributor.localIdA02796-
dc.contributor.localIdA03996-
dc.relation.journalcodeJ00720-
dc.identifier.eissn2233-6087-
dc.identifier.pmid30993937-
dc.subject.keywordDiabetes mellitus-
dc.subject.keywordDiabetes mellitus, type 2-
dc.subject.keywordFatty liver-
dc.subject.keywordLiver diseases-
dc.subject.keywordMetabolic diseases-
dc.subject.keywordNon-alcoholic fatty liver disease-
dc.subject.keywordTherapeutics-
dc.contributor.alternativeNameLee, Byung Wan-
dc.contributor.affiliatedAuthor이병완-
dc.contributor.affiliatedAuthor차봉수-
dc.citation.volume43-
dc.citation.number2-
dc.citation.startPage127-
dc.citation.endPage143-
dc.identifier.bibliographicCitationDIABETES & METABOLISM JOURNAL, Vol.43(2) : 127-143, 2019-
dc.identifier.rimsid62317-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.